SAMPLE IMMUNIZATION RECORD

| (continued) | |
|--|----------------------------|
| This is a SAMPLE immunization | record form. If reproduced |
| for use by a college or university | health |
| ce | |
| | |
| n | |
| ter, please insert your health cer This form should not be returned PART I | |
| Name | |
| | |
| | |
| | |
| First Name | |
| Middle Name | |
| | |
| | |
| | |
| Last | |
| Na | |
| me Address | |
| Addioos | |
| | |
| | |
| | |
| Street | |
| City State | |
| Zip | |

Date of Entry ____/___ Date of Birth ____/___

M Y

School ID#

M

D Y

| Status: | Part | | |
|--|--|---|--------------------------|
| time | Full | | |
| time Graduate PART II | | Undergraduate | Professional |
| CARE PROAL All information A. MMR (MEASLES) (Two doses restudents born | OVIDER on must be S, MUN required a | | |
| 1. Dose 1 given | at age 1 | 2 months or later . | |
| #1/ M D 2. Dose 2 given | at least 2 | 28 days after first dose . | |
| | | | |
| #2/ | , —— | | |
| В | Y | | |
| , - | | at least 28 days apart. ⁻ website for details.) | Three primary series are |
| OPV alone (d | oral Sabir | three doses): | |

| #1/ #2 |
|---|
| /#3/ |
| M D Y |
| M D Y |
| M D Y |
| 2. |
| IPV/OPV sequential: |
| IPV #1/ IPV #2/ OPV #3 |
| /O |
| PV #4/ |
| M D Y |
| M D Y |
| M D Y |
| M D Y |
| 3. |
| IPV alone (injected Salk four doses): |
| #1/ #2 |
| // #3/ # |
| 4 |
| |
| M D Y |
| M D Y |
| M D Y |
| M D Y |
| C |
| |
| |
| VARICELLA |
| (Birth in the U.S. before 1980, a history of chicken |
| pox, a positive varicella antibody, or two doses of vaccine meets the |
| requirement.) |
| 1. |
| |
| History of Disease Yes No or Birth in U.S. before 1980 |
| Yes No |
| 2. |
| Varicella antibody |
| / |
| Result: |
| |
| Reactive Non |
| - - |
| reactive |
| M D Y |

| 3. |
|---|
| Immunization |
| a. Dose #1. |
| |
| |
| |
| |
| #1 / / |
| #1/ M D Y |
| b. Dose #2 given at least 12 weeks after first dose ages 1 |
| - |
| 12 years. |
| - |
| |
| # |
| 2 |
| _ |
| |
| and at least 4 weeks after first dose if age 13 years or older. |
| M D Y |
| D |
| |
| • |
| TETANUS, DIPHTHERIA, PERTUSSIS |
| 1. |
| Primary series completed? Yes No |
| Date of |
| last |
| |
| dose |
| in series: |
| / |
| 2. |
| Date of most recent booster dose: |
| |
| // M D Y |
| Type of booster: Td Tdap |
| Tdap booster recommended for ages 11 |
| |
| - 64 unloss contraindi |
| 64 unless contraindi |

cated.

| E |
|---|
| . HUMAN PAPILLOMAVIRUS VACCINE (HPV2 or HPV4) (Three doses of vaccine for females and males 11 |
| 26 years of age at 0, 1 |
| 2, and 6 month intervals.) Immunization (indicate which preparation) Quadrivalent (HPV4) or Bivalent (HPV2) _ |
| a. Dose #1/ b. Dose #2/ c. Dose #3 M D Y M D Y M D Y F INFLUENZA Date of last dose:// |
| M D Y Trivalent inactivated influenza vaccine (TIV) Live attenuated influenza vaccine (LAIV) |
| G . HEPATITIS A 1. Immunization (hepatitis A) a. Dose #1/ b. Dose #2/ M D Y M D Y 2. |
| Immunization (Combined hepatitis A and B vaccine) a. Dose #1/ b. Dose #2/ c. Dose #3// |

| M | | Y | | | | |
|------------|---------------------|-----------|---------------------|-----------------|-----------------------------|--------|
| M H | D | Υ | | | | |
| | | | | | | |
| HEPA | ATITIS B | | | | | |
| (| | | | | | |
| | _ | | care professiona | | | |
| stua | ents. Inr | ee aose | s of vaccine or tw | o doses of adul | t vaccine in adolescents 11 | |
| - 15 ye | ears of ag | ge, or a | | | | |
| • | ive hepa | - | | | | |
| s B s | urface ar | ntibody i | meets the require | ment.) | | |
| 1. | | // | 5) | | | |
| | unizatior ose #1 | ı (nepat | itis B) | | | |
| | //_ | | | | | |
| | ose #2 | | - | | | |
| | JJ_ | | _ | | | |
| | se #3 | | | | | |
| | //_ | | _ | | | |
| | D | | | | | |
| | D | | | | | |
| | D t formula | | Child formula | ntion | Adult formulation | Child |
| | ulation _ | | | 111011 | Adult formulation | Cilliu |
| | | | Child formulation | 1 | | |
| 2. | | · | | · | | |
| lmm | unizat | | | | | |
| ion (| Combine | d hepat | itis A and B vaccir | ie) | | |
| a. Do | se #1 | | | | | |
| | //_ | | _ | | | |
| | ose #2 | | | | | |
| | //_ | | - | | | |
| | se #3 / / | | | | | |
| M | | Υ | - | | | |
| М | D , | Υ | | | | |
| M | D | Υ | | | | |
| 3. | | | | | | |
| Нера | | | | | | |
| | face anti | ibody | | | | |
| Date | , , | | | | | |
| Doo: | //_ | ctivo | - Nan | | | |
| Resu | п. кеа | ctive | Non | | | |

| - |
|--|
| reactive |
| reactive M D Y |
| I |
| |
| PNEUMOCOCCAL POLYSACCHARIDE VACCINE |
| (One dose for members of high |
| - |
| risk groups.) |
| Date |
| // M D Y |
| |
| J |
| . MENUNCOCOCCAL OLIA DRIVALENT |
| MENINGOCOCCAL QUADRIVALENT |
| (A, C, Y, W |
| 135) One or 2 doses for all college students |
| - 133) One of 2 doses for all conege students |
| revaccinate every 5 years if increased risk continues. |
| 1. |
| Quadrivalent conjugate (preferred; administer simultaneously with Tdap if p |
| ossible). |
| |
| a. Dose #1/ b. Dose #2/ M D Y |
| M D Y |
| 2. |
| Quadrivalent polysaccharide (acceptable alternative if conjugate not available). |
| Date |
| / |
| |
| M D Y |